关键词：胃癌；恶性细胞；幽门螺旋杆菌；细菌感染
摘 要：Gastric cancer is also called as gastric adenocarcinoma, in which malignant cells form inside the stomach. It is the fifth most common type of cancer worldwide and mostly affects men over the age of 55 years or older. H. pylori bacterial infections are a major risk factor for gastric cancer. Some of the other risk factors include an unhealthy lifestyle, age, male sex, family history, and low socioeconomic status. Some of the symptoms of gastric cancer include indigestion, dysphagia, hematemesis, weight loss, inanition bleeding in the stomach, and intrahepatic and extrahepatic jaundice. It is treated with targeted, chemotherapeutic, surgical and radiation therapies.
目 录：

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

PART 05: Disease overview

Understanding the disease

Pathophysiology

Causes

Signs and symptoms

Diagnosis

Staging

Japanese staging system

Treatment

Epidemiology

Economic burden

PART 06: Pipeline portfolio

Information on pipeline candidates

PART 07: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 08: Market segmentation by molecule type

Small molecules

Biologics

PART 09: Market segmentation by route of administration

Oral

Parenteral

PART 10: Market segmentation by lines of chemotherapy

First-line chemotherapy

Second-line chemotherapy

PART 11: Geographical segmentation

Global gastric cancer drugs market by geographical

segmentation 2015-2020

Gastric cancer drugs market in APAC

Gastric cancer drugs market in Japan

Gastric cancer drugs market in China

Gastric cancer drugs market in Americas

Gastric cancer drugs market in EMEA

PART 12: Market drivers

Promising drug pipeline

Unmet medical needs

Increase in patient population

Patient assistance programs

PART 13: Impact of drivers

PART 14: Market challenges

High cost of drugs

Adverse side effects

Shortage of drugs

Delayed diagnosis

PART 15: Impact of drivers and challenges

PART 16: Market trends

Rise in public awareness

Use of off-label drugs

Intense competition among vendors

PART 17: Vendor landscape

Competitive scenario

Market share analysis 2015

Eli Lilly

PART 18: Key vendor analysis

Eli Lilly

F. Hoffmann-La Roche

Otsuka Holdings

Sanofi

Other prominent vendors

PART 19: Appendix

List of abbreviation

PART 20: Explore Technavio